Back Pain News and Research RSS Feed - Back Pain News and Research

Back pain is a very common problem affecting almost all individuals at some point in their lives. Back pain most commonly affects the lower back although it can be felt anywhere along the spine. An individual may experience aching, tension and stiffness that lasts for only a few days or weeks, or these symptoms may continue for many months or even years.

In most cases, back pain does not have a specific or serious cause and is often referred to as 'non-specific' pain. However, the pain can be triggered or worsened by, for example, a poor sitting or standing posture or bending or lifting incorrectly.

The use of painkillers and keeping active is often sufficient for the condition to resolve within 12 weeks. If back pain lasts longer than this, in which case it is termed chronic pain, an individual should visit their doctor. If the back pain is accompanied by any one of a fever, unexplained weight loss, swelling in the back, chest pain, leg pain, loss of bladder or bowel control, inability to pass urine, or pain that is worse at night, then medical help should be sought immediately. These are termed 'red flag symptoms' and could be a sign of something more serious such as rheumatoid arthritis, a slipped disc or osteoporosis.

People can reduce their chance of developing back pain by engaging in regular exercise, particularly swimming or walking, taking care to bend from the knees and hips rather than the back and maintaining a good posture.
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system. [More]
Study shows link between upright locomotion and spinal health

Study shows link between upright locomotion and spinal health

A Simon Fraser University researcher has uncovered what may be the first quantified evidence demonstrating a relationship between upright locomotion and spinal health. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Two UC Davis researchers awarded grant to help improve surveillance for patients with small lung nodules

Two UC Davis researchers awarded grant to help improve surveillance for patients with small lung nodules

Two UC Davis researchers will help run a major national study to improve surveillance practices for patients with small lung nodules identified on CT imaging and extremely low risk for lung cancer. [More]
Board-certified physiatrist Brian Fellechner joins St. Luke’s University Health Network

Board-certified physiatrist Brian Fellechner joins St. Luke’s University Health Network

St. Luke’s University Health Network is pleased to welcome board-certified physiatrist Brian Fellechner, DO, to its medical staff. A graduate of the Philadelphia College of Osteopathic Medicine, Dr. Fellechner completed his residency in physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School in Newark, New Jersey where he served as chief resident at the Kessler Institute for Rehabilitation. [More]
ACA calls for 'conservative care first' approach to low-back pain

ACA calls for 'conservative care first' approach to low-back pain

The American Chiropractic Association, in response to recent research calling into question the efficacy of acetaminophen in the management of spinal pain, strongly encourages patients and healthcare providers to consider the benefits of a conservative approach to back pain. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Early and guideline adherent physical therapy reduces costs, resources in LBP patients

Early and guideline adherent physical therapy reduces costs, resources in LBP patients

A study in the scientific journal BMC Health Services Research shows that early and guideline adherent physical therapy following an initial episode of acute, nonspecific low back pain (LBP) resulted in substantially lower costs and reduced use of health care resources over a 2-year period. [More]
Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. [More]
Phone counseling can boost recovery, reduce pain in patients after spinal surgery

Phone counseling can boost recovery, reduce pain in patients after spinal surgery

Research by Johns Hopkins scientists suggests that having a short series of phone conversations with trained counselors can substantially boost recovery and reduce pain in patients after spinal surgery. [More]
Zyga reports commercial use of modernized SImmetry Sacroiliac Joint Fusion System for low back pain

Zyga reports commercial use of modernized SImmetry Sacroiliac Joint Fusion System for low back pain

Zyga Technology, Inc., a medical device company focused on the design, development and commercialization of minimally invasive devices to treat underserved conditions of the lumbar spine, today announced the launch and first commercial use of an updated SImmetry Sacroiliac Joint Fusion System. The surgery was performed by Dr. Brett Menmuir. [More]
Obesity, smoking, alcohol abuse, depressive disorders are risk factors for low back pain

Obesity, smoking, alcohol abuse, depressive disorders are risk factors for low back pain

New research presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) identifies nicotine dependence, obesity, alcohol abuse and depressive disorders as risk factors for low back pain, a common condition causing disability, missed work, high medical costs and diminished life quality. [More]
New research shows spinal surgery improves sexual function, reduces low back pain

New research shows spinal surgery improves sexual function, reduces low back pain

Chronic low back pain can limit everyday activities, including sex. New research presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), found that 70 percent of patients consider sexual activity "relevant" to their life quality, and patients who receive surgical treatment for spinal spondylolisthesis (DS) and spinal stenosis (SS)--common degenerative conditions most often occurring in older adults--were twice as likely to report no pain during sex. [More]
MIS TLIF surgery results in less pain, shorter hospital stay and faster recovery

MIS TLIF surgery results in less pain, shorter hospital stay and faster recovery

A minimally invasive spinal fusion back surgery results in less blood loss, less postoperative pain, smaller incisions, a shorter hospital stay and faster recovery and return to work. [More]

Study compares HA injections and triamcinolone in improving pain in patients with lumbar ZJT arthropathy

A study presented at AAP 2015 San Antonio compares the effectiveness of HA injections to triamcinolone in improving pain and function in patients with lumbar ZJT arthropathy. [More]
Loyola surgeon describes the immense benefits of minimally invasive spinal fusion surgery

Loyola surgeon describes the immense benefits of minimally invasive spinal fusion surgery

A minimally invasive spinal fusion back surgery results in less blood loss, less postoperative pain, smaller incisions, a shorter hospital stay and faster recovery and return to work. [More]
BMC researchers to play key role in examining best treatment for acute low back pain

BMC researchers to play key role in examining best treatment for acute low back pain

Boston Medical Center researchers are part of a national clinical trial that will examine how best to treat acute low back pain and potentially prevent it from being chronic. BMC will receive $2.3 million for its role in the five-year study that was recently approved for a $14 million award by the Patient-Centered Outcomes Research Institute. [More]
FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). [More]
NHS savings plan led to cuts in some ‘ineffective’ treatments

NHS savings plan led to cuts in some ‘ineffective’ treatments

The drive to reduce NHS spending led to a drop in some treatments considered ‘low-value’, according to new research. [More]
Advertisement
Advertisement